Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Operating Income 2020–2024
Inhibikase Therapeutics Inc. annual/quarterly operating income history and growth rate from 2020 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Inhibikase Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -17.8 M, a 22.22% increase year-over-year.
- Inhibikase Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -56.0 M, a 174.32% increase year-over-year.
- Inhibikase Therapeutics Inc. annual operating income for 2024 was -28.6 M, a 42.31% increase from 2023.
- Inhibikase Therapeutics Inc. annual operating income for 2023 was -20.1 M, a 10.82% increase from 2022.
- Inhibikase Therapeutics Inc. annual operating income for 2022 was -18.1 M, a 22.77% increase from 2021.
- Inhibikase Therapeutics Inc. annual operating income for 2021 was -14.8 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Inhibikase Therapeutics Inc. Operating Income — FAQ
Inhibikase Therapeutics Inc. (IKT) operating income over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
What is Inhibikase Therapeutics Inc.'s operating income?
Inhibikase Therapeutics Inc. (IKT) reported operating income of -$29M for fiscal 2024.
Where can I see IKT's operating income history?
The chart and table above show Inhibikase Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.